98 related articles for article (PubMed ID: 6548867)
21. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
22. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
Livi L; Saieva C; Borghesi S; Paoletti L; Meattini I; Rampini A; Petrucci A; Scoccianti S; Paiar F; Cataliotti L; Leonulli BG; Bianchi S; Biti GP
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):705-9. PubMed ID: 18191333
[TBL] [Abstract][Full Text] [Related]
23. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
[TBL] [Abstract][Full Text] [Related]
24. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
[TBL] [Abstract][Full Text] [Related]
25. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
27. Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer.
Beex LV; Hermus AR; Pieters GF; van Hoesel QG; Nooy MA; Mignolet F
Eur J Cancer; 1992; 28(2-3):686-90. PubMed ID: 1591094
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer.
Markiewicz DA; Fox KR; Schultz DJ; Harris EE; Haas JA; Glick JH; Solin LJ
Cancer J Sci Am; 1998; 4(3):185-93. PubMed ID: 9612601
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
[TBL] [Abstract][Full Text] [Related]
30. Second malignancies after CMF for resectable breast cancer.
Valagussa P; Tancini G; Bonadonna G
J Clin Oncol; 1987 Aug; 5(8):1138-42. PubMed ID: 3625243
[TBL] [Abstract][Full Text] [Related]
31. Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Canobbio L; Conte PF; Cusimano MP; Fusco V; Gulisano M; Lionetto R
Am J Clin Oncol; 1987 Oct; 10(5):404-6. PubMed ID: 3310605
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
Lokich J; Bern M; Anderson N; Wallach S; Moore C; Beauchamp K; Williams D
Cancer; 1989 Mar; 63(5):822-4. PubMed ID: 2914289
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
35. Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.
Montemurro F; Gatti M; Redana S; Jacomuzzi ME; Nanni D; Durando A; Popolo M; Ponzone R; Rossi A; Albieri V; Valabrega G; Sismondi P; Gabriele P; Aglietta M
J Chemother; 2006 Feb; 18(1):90-7. PubMed ID: 16572899
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
[TBL] [Abstract][Full Text] [Related]
37. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
38. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.
Vélez-García E; Carpenter JT; Moore M; Vogel CL; Marcial V; Ketcham A; Singh KP; Bass D; Bartolucci AA; Smalley R
Eur J Cancer; 1992; 28A(11):1833-7. PubMed ID: 1389521
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
40. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
